Mortality and morbidity
|
|
|
Premature mortality from noncommunicable disease |
(1) A 25% relative reduction in the overall mortality from cardiovascular diseases, cancer, diabetes, or chronic respiratory diseases |
(1) Unconditional probability of dying between ages of 30 and 70 from cardiovascular diseases, cancer, diabetes or chronic respiratory diseases |
Additional indicator
|
(2) Cancer incidence, by type of cancer, per 100 000 population |
Behavioural risk factors
|
|
|
Harmful use of alcohol1
|
(2) At least 10% relative reduction in the harmful use of alcohol,2 as appropriate, within the national context |
(3) Total (recorded and unrecorded) alcohol per capita (aged 15+ years old) consumption within a calendar year in litres of pure alcohol, as appropriate, within the national context |
(4) Age-standardized prevalence of heavy episodic drinking among adolescents and adults, as appropriate, within the national context |
(5) Alcohol-related morbidity and mortality among adolescents and adults, as appropriate, within the national context |
Physical inactivity |
(3) A 10% relative reduction in prevalence of insufficient physical activity |
(6) Prevalence of insufficiently physically active adolescents, defined as less than 60 minutes of moderate to vigorous intensity activity daily |
(7) Age-standardized prevalence of insufficiently physically active persons aged 18+ years (defined as less than 150 minutes of moderate-intensity activity per week, or equivalent) |
Salt/sodium intake |
(4) A 30% relative reduction in mean population intake of salt/sodium3
|
(8) Age-standardized mean population intake of salt (sodium chloride) per day in grams in persons aged 18+ years |
Tobacco use |
(5) A 30% relative reduction in prevalence of current tobacco use in persons aged 15+ years |
(9) Prevalence of current tobacco use among adolescents |
(10) Age-standardized prevalence of current tobacco use in persons aged 18+ years |
Biological risk factors
|
|
|
Raised blood pressure |
(6) A 25% relative reduction in the prevalence of raised blood pressure or contain the prevalence of raised blood pressure according to national circumstances |
(11) Age-standardized prevalence of raised blood pressure among persons aged 18+ years (defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg) and mean systolic blood pressure |
Diabetes and obesity4
|
(7) Halt the rise in diabetes and obesity |
(12) Age-standardized prevalence of raised blood glucose/diabetes among persons aged 18+ years (defined as fasting plasma glucose concentration ≥ 7.0 mmol/L (126 mg/dL) or on medication for raised blood glucose) |
(13) Prevalence of overweight and obesity in adolescents (defined according to the WHO growth reference for school-aged children and adolescents, overweight - one standard deviation body mass index for age and sex, and obese - two standard deviations body mass index for age and sex) |
(14) Age-standardized prevalence of overweight and obesity in persons aged 18+ years (defined as body mass index ≥ 25 kg/m² for overweight and body mass index ≥ 30 kg/m² for obesity) |
Additional indicators
|
(15) Age-standardized mean proportion of total energy intake from saturated fatty acids in persons aged 18+ years5
|
(16) Age-standardized prevalence of persons (aged 18+ years) consuming less than five total servings (400 g) of fruit and vegetables per day |
(17) Age-standardized prevalence of raised total cholesterol among persons aged 18+ years (defined as total cholesterol ≥ 5.0 mmol/L or 190 mg/dL); and mean total cholesterol concentration |
National systems response
|
|
|
Drug therapy to prevent heart attacks and strokes |
(8) At least 50% of eligible people receive drug therapy and counselling (including glycaemic control) to prevent heart attacks and strokes |
(18) Proportion of eligible persons (defined as aged 40 years and older with a 10-year cardiovascular risk ≥ 30%, including those with existing cardiovascular disease) receiving drug therapy and counselling (including glycaemic control) to prevent heart attacks and strokes |
Essential noncommunicable disease medicines and basic technologies to treat major noncommunicable diseases |
(9) An 80% availability of the affordable basic technologies and essential medicines, including generics, required to treat major noncommunicable diseases in both public and private facilities |
(19) Availability and affordability of quality, safe and efficacious essential noncommunicable disease medicines, including generics, and basic technologies in both public and private facilities |
Additional indicators
|
(20) Access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics (excluding methadone) per death from cancer |
(21) Adoption of national policies that limit saturated fatty acids and virtually eliminate partially hydrogenated vegetable oils in the food supply, as appropriate, within the national context and national programmes |
(22) Availability, as appropriate, if cost-effective and affordable, of vaccines against human papillomavirus, according to national programmes and policies |
(23) Policies to reduce the impact on children of marketing of foods and non-alcoholic beverages high in saturated fats, trans fatty acids, free sugars, or salt |
(24) Vaccination coverage against hepatitis B virus monitored by number of third doses of Hep-B vaccine (HepB3) administered to infants |
(25) Proportion of women between the ages of 30-49 screened for cervical cancer at least once, or more often, and for lower or higher age groups according to national programmes or policies |